Myriad Genetics, Inc. (MYGN)
After hours:
| Previous Close | 15.12 |
| Open | 15.10 |
| Bid | 15.42 x 200 |
| Ask | 15.53 x 100 |
| Day's Range | 15.10 - 15.67 |
| 52 Week Range | 14.72 - 29.30 |
| Volume | |
| Avg. Volume | 797,604 |
| Market Cap | 1.41B |
| Beta (5Y Monthly) | 1.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.28 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.08 |
GlobeNewswireMyriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor typesSALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Re
- GlobeNewswire
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that the Prequel® Prenatal Screen is now available at eight weeks into pregnancy. Enabled by its AMPLIFY™ technology, Prequel is the first and only prenatal cell-free DNA (cfDNA) screen available at eight-weeks gestational age. “Previously, I would schedule my patients to come in at eight weeks for their first prenatal appointment; then, I would as
